Changes in Beneficial Ownership · 4
IRIDEX Corporation
IRIXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-16
- Issuer
- IRIDEX CORP
- Issuer CIK
- 0001006045
- Trading symbol
- IRIX
Reporting owner 1
- Name
- Dizon Romeo R
- Reporting owner CIK
- 0001658282
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW, CA, 94043
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-16 | P · Form 4 | 7,900 | A | 0.63 | 185,306 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Signature 1
- Signed
- /s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon
- Date
- 2026-09-16
Company context
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Current securities
Recent company filings
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 2, 2026
- 10-Q filingAug 18, 2026
- Results of Operations and Financial ConditionAug 18, 2026
- Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureJul 16, 2026
- SCHEDULE 13D/A - filed by Novel Inspiration International Co., Ltd. regarding IRIDEX CORPJul 13, 2026